Three-dimensional greyscale transrectal ultrasound-guidance and biopsy core preembedding for detection of prostate cancer: Dutch clinical cohort study

Table 2 Detection rate of all prostate cancer and clinically significant prostate cancer

Whole group
Detection rate of PCa
Biopsy cohort:	n/N (%)	Crude OR (95% CI)	aOR^a (95% CI)
Total	568/1618 (35.1%)
3D TRUS	183/469 (39.0%)	1.27 (1.02–1.59)	1.33 (1.03–1.72)
2D TRUS	385/1149 (33.5%)	Reference	Reference
Detection rate of clinically significant PCa
	n/N (%)	Crude OR (95% CI)	aOR^a (95% CI)
Total	335/1618 (20.7%)
3D TRUS	117/469 (24.9%)	1.42 (1.10–1.83)	1.47 (1.09–1.98)
2D TRUS	218/1149 (19.0%)	Reference	Reference
Biopsy naive group
Detection rate of PCa
	n/N (%)	Crude OR (95% CI)	aOR^b (95% CI)
Total	466/1238 (37.6%)
3D TRUS	151/375 (40.3%)	1.17 (0.92–1.50)	1.20 (0.90–1.60)
2D TRUS	315/863 (36.5%)	Reference	Reference
Detection rate of clinically significant PCa
	n/N (%)	Crude OR (95% CI)	aOR^b (95% CI)
Total	295/1238 (23.8%)
3D TRUS	105/375 (28.0%)	1.38 (1.04–1.82)	1.41 (1.02–1.96)
2D TRUS	190/863 (22.0%)	Reference	Reference
Prior negative group
Detection rate of PCa
	n/N (%)	Crude OR (95% CI)	aOR^c (95% CI)
Total	102/380 (26.8%)
3D TRUS	32/94 (34.0%)	1.59 (0.96–2.64)	1.78 (1.04–3.04)
2D TRUS	70/286 (24.5%)	Reference	Reference
Detection rate of clinically significant PCa
	n/N (%)	Crude OR (95% CI)	aOR^d (95% CI)
Total	40/380 (10.5%)
3D TRUS	12/94 (12.8%)	1.35 (0.66–2.77)	–
2D TRUS	28/286 (9.8%)	Reference	Reference

^aadjusted Odds Ratio: adjusted for age, DRE, prostate volume and physician (PSA and Type of biopsy session resulted in < 10% change in β)
^b adjusted Odds Ratio: adjusted for age, DRE and prostate volume and physician (PSA resulted in < 10% change in the β)
^c adjusted Odds Ratio: adjusted for age and Log (prostate volume), (age, PSA, DRE and physician resulted in < 10% change in the β)
^d the number of events per variable are too low to be analyzed in multivariable logistic regression analysis

ISSN: 1471-2490